Tradea is used in the therapy of hyperactivity and attention deficit disorder. It is a powerful CNS stimulant that is prescribed to patients with narcolepsy, apathy, complications after a stroke. It is possible to use for children and adults.
Active ingredient and product forms
The active ingredient of Tradea Medication is methylphenidate in hydrochloride form. The substance was first synthesized in 1944, and since 1961, it began to be used in the United States to treat hyperactivity. In chemical nature, it is a methyl ester.
Methylphenidate is a psychostimulant, a derivative of piperidine and phenylethylamine. The substance is absorbed into the systemic bloodstream through the gastrointestinal tract. Maximum bioavailability is 50%, average - 30%. The therapeutic effect lasts for 10-12 hours. The active substance is metabolized in the liver and excreted with urine through the kidneys.
The drug is available in two dosages:
- Tradea 10 mg for children;
- Tradea 54 mg for adults.
Form release - tablets for oral administration, packed in cartons.
Mechanism of action
Methylphenidate hydrochloride stimulates the nervous system similar to amphetamine and its derivatives. Tradea LP is an effective inhibitor of norepinephrine hormone reuptake. The substance affects subcortical structures and the cortex of the large hemispheres. Blocking dopamine transport leads to activation of the parasympathetic nervous system, which causes a mild sedative effect. Against the background of admission, the concentration of attention increases, sleep normalizes and anxiety is relieved.
Indications for taking tablets Tradea LP
The drug based on methylphenidate hydrochloride is prescribed for the following indications:
- attention deficit disorder;
- asthenic conditions;
- depression of the nervous system against the background of taking antipsychotic drugs;
- narcolepsy - a sleep disorder characterized by sudden attacks of sleepiness during the day.
Contraindications to use
Tradea LP tablets are not prescribed if:
- intolerance to the main or auxiliary components;
- suicidal ideation;
- prolonged depression;
- acute psychosis;
- angina pectoris.
The minimum age limit is six years. Use in young children is not allowed due to the lack of data about the possible negative impact on the developing body.
The minimum doses of the drug are well tolerated by patients. Undesirable effects may occur during therapy with high doses. The probability of side effects is higher during the first days of therapy. Against the background of treatment, there may be disturbances:
- abdominal pain;
- worsening of appetite;
- chest pain;
- frequent urge to urinate;
- skin itching;
- visual impairment.
In children, against the background of long-term treatment, growth retardation is possible. This is associated with the suppression of the production of the somatotropin hormone. In case of side effects, it is recommended to reduce the dose of the drug.
The daily dose of the active substance is selected individually, taking into account the age and severity of symptoms. If during treatment with Tradea tablets no improvement occurs within a month, the drug shall be discontinued.
There is no convincing data about the safety of methylphenidate during pregnancy, therefore the drug is not prescribed while waiting for a child. The active ingredient passes unimpeded into the breast milk. Lactation is stopped for the duration of treatment. The drug may be addictive, so it is used strictly under the supervision of a doctor.